A Phase Ⅱa Clinical Study of CL-197 Capsules

NCT07308782 | Recruiting Phase 2

• 1 other identifier: GB-CL-197-102
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency virus type 1 (HIV-1) infection.

Conditions

HIV-1 Infection

Keywords

HIV-1 infection; CL-197

Outcome Measures

Primary Outcomes (1)

• Change from baseline in log10 value of HIV-1 Ribonucleic acid (RNA) on Day 8

  Baseline and Day 8.

Secondary Outcomes (7)

• Change from baseline in log10 value of HIV-1 RNA on Day 11

  Baseline and Day 11.

• Change from baseline in CD4+ cell count on Day 13

  Baseline and Day 13.

• Incidence of adverse events (AEs) / serious AEs

  Day 13.

• Time to Maximum Concentration (Tmax) of CL -197

  Up to 13 days post-dose.

• Elimination Half-Life (t1/2) of CL -197

  Up to 13 days post-dose.

Study Arms (1)

CL-197 capsules

EXPERIMENTAL

Drug: CL-197 capsules

Interventions

CL-197 capsules DRUG

Participants will take a single dose of CL-197 capsules at a dose of 10 mg, 30 mg or 60 mg, orally on an empty stomach.

CL-197 capsules

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Participants aged 18-60 (including boundary values), both male and female.
• Body mass index (BMI) range between 18.5-29.9 (including the boundary value). Body weight ≥ 50.0 kg for men and ≥ 45.0 kg for women.
• Participants diagnosed with HIV-1 infection before screening, and never received any anti-HIV drugs or HIV-related vaccine therapy (including investigational or other unmarketed anti-HIV drugs or vaccines) before screening.
• Participants who agree not to receive other anti-HIV drugs during the trial period (from signing the informed consent form until the Day 13 sampling).
• CD4 cell count \> 200 cells/μL at screening.
• Women of childbearing potential (WOCBP) must have adopted effective non-drug contraceptive measures, have a negative serum pregnancy test at screening/baseline, and be willing to use appropriate effective methods of contraception from signing the informed consent form until 3 months after the last dose of the study drug. Male study participants must be willing to refrain from fathering children and voluntarily use effective contraception during the trial and until 3 months after the last dose of the study drug, or have been surgically sterilized.
• Participants who understand and sign the informed consent form.

You may not qualify if:

• Diagnosis of acute HIV-1 infection, or presence of an AIDS-defining disease at enrollment, or history of an opportunistic infection within 3 months prior to enrollment with the condition remaining unstable within 4 weeks prior to enrollment.
• Had pre-exposure prophylaxis (PrEP) and/or post-exposure prophylaxis (PEP) treatment within 1 month prior to screening.
• Had any clinically significant disease (including cardiovascular, respiratory, digestive, endocrine/metabolic, neurological/psychiatric, hematological, and immune system diseases, etc.) that is poorly controlled, as determined by the investigator at screening.
• Resting systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, or heart rate \> 100 beats per minute, or heart rate \< 50 beats per minute, or QTcF (QT interval corrected for heart rate according to Fridericia's formula) \> 450 ms, or fasting blood glucose ≥ 7.0 mmol/L.
• History of severe allergy (immediate, life-threatening systemic anaphylaxis) to drugs (e.g., aspirin or cephalosporin antibiotics), other drug components (e.g., lactose or gelatin), or food, or history of allergic diseases requiring medication control (e.g., asthma, urticaria, atopic dermatitis/eczema, etc.) prior to screening.
• Had major gastrointestinal surgery within 6 months prior to screening (except uncomplicated appendectomy or cholecystectomy), or any surgery that could affect drug absorption, distribution, metabolism and excretion; or planned elective surgery during the trial period, as determined by the investigator at screening.
• History of malignancy (except carcinoma in situ of the cervix treated with conization, or radically resected basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ \[Bowen's disease\] of the skin).
• Hepatitis B surface antigen (HBsAg) positive at screening, or active syphilis, or Hepatitis C virus (HCV) antibody positive, or previous interferon treatment for HBV infection leading to HBsAg seroconversion.
• Hemoglobin (Hb) \< 110 g/L, or white blood cell (WBC) count \< 3 × 10\^9/L, or absolute neutrophil count (ANC) \< 1 × 10\^9/L, or platelet (PLT) count \< 100 × 10\^9/L at screening.
• Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 2.5 times upper limit of normal (ULN), or total bilirubin (TBIL) ≥ 1.5 × ULN at screening.
• Serum creatinine (SCr) \> 1.1 × ULN, or creatinine clearance (Ccr) \< 60 mL/min (calculated by Cockcroft-Gault formula) at screening.
• Participants smoke more than 5 cigarettes daily on average within 3 months prior to screening, or may be unwilling to stop using any tobacco products during drug administration and sampling periods.
• Drinking more than 14 units of alcohol (1 unit of alcohol ≈ 360 mL of beer with 5% alcohol, or 45 mL of liquor with 40% alcohol, or 150 mL of wine with 12% alcohol) within 3 months prior to screening on average, or positive alcohol breath test at screening or baseline, or unwillingness to stop using any alcohol-containing products during hospitalization.
• Excessive consumption of tea, coffee, and/or caffeine-containing beverages (averaging more than 8 cups per day, 1 cup ≈ 250 mL) within 3 months prior to screening on average, or unwillingness to stop consuming tea, coffee, and/or caffeine-containing beverages during hospitalization.
• Participants with consumption of pitaya, mango, pomelo, carambola, or foods/beverages prepared from them, or foods/beverages containing xanthine, caffeine, or alcohol (including chocolate, tea, coffee, cola, cocoa, etc.), or any other special diet that may affect drug absorption, distribution, metabolism, or excretion within 48 hours prior to the first dose of the investigational product, or unwillingness to stop using them during hospitalization.

Sponsors & Collaborators

• Henan Genuine Biotech Co., Ltd.: lead

Study Sites (1)

Beijing Youan Hospital, Capital Medical University

Beijing, China

RECRUITING

Central Study Contacts

Ping DU

CONTACT

8618810261827; pingdu2012@163.com

Tong Zhang

CONTACT

8613601072376; zt_doc@163.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 26, 2025
• First Posted: December 30, 2025
• Study Start: November 29, 2025
• Primary Completion (Estimated): December 1, 2026
• Study Completion (Estimated): March 1, 2027
• Last Updated: January 6, 2026

Record last verified: 2025-12

Locations

CN (1)